Skip to content

IPHA

Innate Pharma SA

NASDAQ · Healthcare · Biotechnology · FR

$1.90
−0.52%
Ask drillr

Latest reported

Last report date
Sep 17, 2026
EPS actual
-$0.24
EPS estimate
-$0.29
Revenue actual
$6.5M
Revenue estimate
$6.4M

Track record

Trailing twelve quarters

EPS beats (12Q)
2
EPS misses (12Q)
1
EPS in line (12Q)
1
Avg surprise (4Q)
-10.3%
Revenue beats (12Q)
5

Analyst ratings

Sell-side consensus

Consensus
Buy
Price target
$8.00
PT range
$7.00 – $9.00
Analysts
2
2 Buy0 Hold0 Sell
Reported history
Report dateEPS estimateEPS actualSurpriseRevenue actual
Sep 17, 2026-$0.29-$0.24Beat 18.12%$6.5M
May 13, 2026-$0.16-$0.35Miss -116.42%$4.8M
Mar 26, 2026-$0.35-$0.35Beat 0.84%$4.8M
Sep 12, 2024-$0.16$6.6M
Mar 21, 2024-$0.06$11.8M
Jun 30, 2023$0.02$38.6M
Mar 23, 2023-$0.87$9.0M
Sep 15, 2022$0.08$43.2M
Mar 24, 2022-$0.41$3.2M
Jun 30, 2021-$0.36$11.1M
Mar 18, 2021-$0.83$33.1M
Nov 17, 2020-$0.34-$0.15Beat 56.14%$41.3M

Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Sep 17, 2026